TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Joaquin Mateo, Nuria Porta, Ursula Brigid McGovern, Tony Elliott, Robert J Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Anna Varughese, Omi Parikh, Simon J. Crabb, Susana Miranda, George Seed, Claudia Bertan, Aude Espinasse, Peter Chatfield, Diletta Bianchini, Emma Hall, Suzanne Carreira, Johann S. De Bono, on behalf of the TOPARP Investigators Group
Institutions: Institute of Cancer Research, University College Hospital, The Christie Hospital, The Christie NHS Foundation Trust, Beatson West of Scotland Cancer Centre, University of Glasgow, Clatterbridge Cancer Centre NHS Foundation Trust, University of Leeds, Queen's University Belfast, Musgrove Park Hospital, Royal Preston Hospital, University of Southampton, Royal Marsden NHS Foundation Trust
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947143110